Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Recent Posts
- BIOTEC Executive Delegation Strengthens Strategic Research Partnership with CSIRO in Australia
08/20/2026 - Cambridge and BIOTEC Researchers Join Thailand-International Networks to Advance One Health Action against Streptococcus suis: From Research to Prevention
07/17/2026 - Pirbright-BIOTEC African Swine Fever Technical Workshop
06/29/2026